Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 14/20 | 0.54 |
| ▸ | PAK4 | O96013 | 4/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.42 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15383198 | 0.91 | PLK4 (0.54) | PLK4PAK4AURKAAURKBNTRK1 | |
| SCHEMBL174820 | 0.89 | PLK4 (0.54) | PLK4PAK4AURKAAURKBNTRK1 | |
| SCHEMBL173716 | 0.88 | PLK4 (0.58) | PLK4PAK4AURKAAURKBNTRK1 | |
| SCHEMBL173328 | 0.87 | PLK4 (0.47) | PLK4PAK4NTRK1 | |
| SCHEMBL175326 | 0.83 | PLK4 (0.49) | PLK4PAK4AURKAAURKBNTRK1 | |
| SCHEMBL174442 | 0.78 | PLK4 (0.66) | PLK4PAK4 | |
| SCHEMBL175070 | 0.76 | AURKA (0.63) | PLK4PAK4AURKAAURKBNTRK1 | |
| SCHEMBL174494 | 0.76 | PLK4 (0.46) | PLK4PAK4AURKAAURKBNTRK1 | |
| SCHEMBL174860 | 0.76 | PLK4 (0.56) | PLK4PAK4AURKBNTRK1 | |
| SCHEMBL168759 | 0.76 | NTRK1 (0.66) | AURKAAURKBNTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | PLK4 246/4885PAK4 784/4885AURKA 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.